Cargando…

Expanded conventional first trimester screening

OBJECTIVE: The study aims to determine the performance of a five (5) serum marker plus ultrasound screening protocol for T21, T18 and T13. METHOD: Specimens from 331 unaffected, 34 T21, 19 T18 and 8 T13 cases were analyzed for free Beta human chorionic gonadotropin, pregnancy‐associated plasma prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmichael, Jonathan B., Liu, Hsiao‐Pin, Janik, David, Hallahan, Terrence W., Nicolaides, Kypros H., Krantz, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601195/
https://www.ncbi.nlm.nih.gov/pubmed/28613385
http://dx.doi.org/10.1002/pd.5090
_version_ 1783264346740097024
author Carmichael, Jonathan B.
Liu, Hsiao‐Pin
Janik, David
Hallahan, Terrence W.
Nicolaides, Kypros H.
Krantz, David A.
author_facet Carmichael, Jonathan B.
Liu, Hsiao‐Pin
Janik, David
Hallahan, Terrence W.
Nicolaides, Kypros H.
Krantz, David A.
author_sort Carmichael, Jonathan B.
collection PubMed
description OBJECTIVE: The study aims to determine the performance of a five (5) serum marker plus ultrasound screening protocol for T21, T18 and T13. METHOD: Specimens from 331 unaffected, 34 T21, 19 T18 and 8 T13 cases were analyzed for free Beta human chorionic gonadotropin, pregnancy‐associated plasma protein A, alpha‐fetoprotein, placental growth factor and dimeric inhibin A. Gaussian distributions of multiples of the median values were used to estimate modeled false positive and detection rates (DR). RESULTS: For T21, at a 1/300 risk cut‐off, DR of screening with all five serum markers along with nuchal translucency and nasal bone was 98% at a 1.2% false positive rate (FPR). Using a 1/1000 cut‐off, the DR was 99% with a 2.6% FPR. For T18/13 with free Beta human chorionic gonadotropin, pregnancy‐associated plasma protein A, placental growth factor and nuchal translucency at a 1/150 cut‐off, DR was 95% at a 0.5% FPR while at a 1/500 risk cut‐off, DR was 97% at a 1.2% FPR. CONCLUSION: An expanded conventional screening test can achieve very high DRs with low FPRs. Such screening fits well with proposed contingency protocols utilizing cell‐free DNA as a secondary or reflex but also provides the advantages of identification of pregnancies at risk for other adverse outcomes such as early‐onset preeclampsia. © 2017 Eurofins NTD, LLC. Prenatal Diagnosis published by John Wiley & Sons, Ltd.
format Online
Article
Text
id pubmed-5601195
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56011952017-10-03 Expanded conventional first trimester screening Carmichael, Jonathan B. Liu, Hsiao‐Pin Janik, David Hallahan, Terrence W. Nicolaides, Kypros H. Krantz, David A. Prenat Diagn Original Articles OBJECTIVE: The study aims to determine the performance of a five (5) serum marker plus ultrasound screening protocol for T21, T18 and T13. METHOD: Specimens from 331 unaffected, 34 T21, 19 T18 and 8 T13 cases were analyzed for free Beta human chorionic gonadotropin, pregnancy‐associated plasma protein A, alpha‐fetoprotein, placental growth factor and dimeric inhibin A. Gaussian distributions of multiples of the median values were used to estimate modeled false positive and detection rates (DR). RESULTS: For T21, at a 1/300 risk cut‐off, DR of screening with all five serum markers along with nuchal translucency and nasal bone was 98% at a 1.2% false positive rate (FPR). Using a 1/1000 cut‐off, the DR was 99% with a 2.6% FPR. For T18/13 with free Beta human chorionic gonadotropin, pregnancy‐associated plasma protein A, placental growth factor and nuchal translucency at a 1/150 cut‐off, DR was 95% at a 0.5% FPR while at a 1/500 risk cut‐off, DR was 97% at a 1.2% FPR. CONCLUSION: An expanded conventional screening test can achieve very high DRs with low FPRs. Such screening fits well with proposed contingency protocols utilizing cell‐free DNA as a secondary or reflex but also provides the advantages of identification of pregnancies at risk for other adverse outcomes such as early‐onset preeclampsia. © 2017 Eurofins NTD, LLC. Prenatal Diagnosis published by John Wiley & Sons, Ltd. John Wiley and Sons Inc. 2017-07-18 2017-08 /pmc/articles/PMC5601195/ /pubmed/28613385 http://dx.doi.org/10.1002/pd.5090 Text en © 2017 Eurofins NTD, LLC. Prenatal Diagnosis published by John Wiley & Sons, Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Carmichael, Jonathan B.
Liu, Hsiao‐Pin
Janik, David
Hallahan, Terrence W.
Nicolaides, Kypros H.
Krantz, David A.
Expanded conventional first trimester screening
title Expanded conventional first trimester screening
title_full Expanded conventional first trimester screening
title_fullStr Expanded conventional first trimester screening
title_full_unstemmed Expanded conventional first trimester screening
title_short Expanded conventional first trimester screening
title_sort expanded conventional first trimester screening
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601195/
https://www.ncbi.nlm.nih.gov/pubmed/28613385
http://dx.doi.org/10.1002/pd.5090
work_keys_str_mv AT carmichaeljonathanb expandedconventionalfirsttrimesterscreening
AT liuhsiaopin expandedconventionalfirsttrimesterscreening
AT janikdavid expandedconventionalfirsttrimesterscreening
AT hallahanterrencew expandedconventionalfirsttrimesterscreening
AT nicolaideskyprosh expandedconventionalfirsttrimesterscreening
AT krantzdavida expandedconventionalfirsttrimesterscreening